The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis

Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis

September 29, 2015 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rheumatologists know that patients with axial spondyloarthritis (axSpA) experience chronic back pain, spinal stiffness, reduction in mobility and quality of life. Over time, permanent damage to spinal mobility and function can occur due to new bone formation in the spine.

You Might Also Like
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • NSAIDs Effective for Early Axial Spondyloarthritis

The current standard of care for axSpA is non-steroidal anti-inflammatory drugs (NSAIDs). If there is an insufficient response or intolerance to NSAIDs, the next line of treatment is tumor necrosis factor (TNF)–alpha targeted therapies that have demonstrated efficacy in recent trials in non-radiographic axSPA (nr-axSpA) patients. TNF-blocking agents have been approved for this indication in the EU and other countries, but are not yet approved in the U.S.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In this randomized double-blind placebo-controlled clinical trial (GO-AHEAD), we investigated the effect of treatment every four weeks with subcutaneously administered golimumab (GLM), a fully human anti-TNF antibody over 16 weeks in patients with active nr-axSpA. The primary endpoint was ASAS 20 response at Week 16.

Patients were 18–45 years old with a physician’s diagnosis of active nr-axSpA, a disease duration of five years or less since diagnosis and chronic back pain of three months or longer duration. All patients were required to meet either the ASAS classification criterion for a positive MRI and have one of the spondyloarthritis features, or be HLA-B27 positive and have two or more spondyloarthritis features. Patients had active disease at both screening and baseline defined by a total back pain assessment of ≥40 and a BASDAI of ≥4.0 on a visual analog scale (VAS) of 0–10. An additional inclusion requirement was inadequate response or intolerance to at least one NSAID or inability to tolerate a maximal dose of NSAID therapy for 30 days.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment with GLM every four weeks resulted in significant and sustained improvements in signs and symptoms of nr-axSpA through Week 16, with improvement apparent after the first injection of GLM. In this study, GLM was safe, generally well tolerated and consistent with the known safety profile of GLM in other indications.

In total, 71.1% of patients in the GLM group achieved the primary endpoint, the ASAS 20 response, at Week 16 compared with 40.0% in the PBO group. Improvement in ASDAS and BASDAI were already notable by the first post-baseline assessment (Week 4) and were maintained and increased slightly between four and 16 weeks. Treatment effects with GLM were also significant for the key secondary efficacy measures that included the ASAS 40 response, the BASDAI 50 response, ASAS partial remission and SPARCC MRI SI joint score change from baseline to Week 16. Clinically meaningful improvements were observed in multiple other measures of disease activity, physical function and quality of life.

Pages: 1 2 | Single Page

Filed Under: Conditions, Spondyloarthritis

You Might Also Like:
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • NSAIDs Effective for Early Axial Spondyloarthritis
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)